MedWatch

Diagnostics company launches first blood test, doubles workforce and eyes profit

Blusense Diagnostics, a spin-out from the Technical University of Denmark (DTU), has launched its first product - a blood test to diagnose Dengue. The company expects to yield profit around 2022 and employ at least 70 people already next year.

In 2017, Filippo Bosco (middle left), CEO of Blusense Diagnostics, received an innovation prize in Malaysia and DKK 670,000. | Foto: Blusense Diagnostics / PR

Danish Blusense Diagnostics still considers itself a start-up although years of growth and a successful product launch make for a fully established diagnostics company.

"Our organization has obviously grown. We are now around 60 people, which is nearly double the amount we were two years ago," says Filippo Bosco, CEO in Blusense Diagnostics, to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Nye insulintilskud bekymrer Diabetesforeningen

Diabetesforeningen er utilfredse med Medicintilskudsnævnets indstilling til en revurdering af tilskud for diabetesmidler, som patientforeningen anser som en spareøvelse uden hensyntagen til patienterne.

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier